Overview
T-lymphoblastic leukemia (T-ALL) is a hematologic malignancy characterized by the clonal expansion of immature T-lymphocytes. It often presents in children and young adults with a variable prognosis influenced by genetic and molecular factors 12.Diagnosis
Molecular Analysis: Essential for categorization into specific sub-groups based on aberrant transcription factors 2.
Cytogenetic Techniques: Chromosome banding analysis and fluorescence in situ hybridization (FISH) are crucial for detecting recurrent chromosomal abnormalities 2.
Provisional Entities: Consideration of eight provisional T-ALL entities from the 2022 International Consensus Classification, though not yet integrated into WHO guidelines 2.Management
First-Line Treatment: Standard protocols include multi-agent chemotherapy regimens such as vincristine, prednisone, daunorubicin, and asparaginase 1.
Nelarabine: Increasingly used, particularly in relapsed/refractory cases; its role in upfront therapy is under evaluation 1.
Molecular Targeting: Future strategies may incorporate deeper understanding of nelarabine's molecular mechanisms to enhance efficacy 1.Special Populations
Pediatrics: T-ALL predominantly affects children, where standard chemotherapy regimens are highly effective but require careful monitoring 1.
Elderly: Limited specific guidance; treatment approaches may need adjustment due to comorbidities and reduced tolerance to intensive chemotherapy 1.Key Recommendations
Utilize molecular analysis alongside cytogenetic techniques for comprehensive diagnosis and risk stratification in T-ALL patients (Evidence: Strong 2).
Consider nelarabine in the treatment regimen, especially for relapsed/refractory cases, with ongoing evaluation for upfront therapy (Evidence: Moderate 1).
Tailor treatment approaches in pediatric and elderly populations based on individual tolerance and comorbidities (Evidence: Expert opinion 1).References
1 Hormann FM, Rudd SG. Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action. Leukemia 2025. link
2 De Bie J, Quessada J, Tueur G, Lefebvre C, Luquet I, Toujani S et al.. Cytogenetics in the management of T-cell acute lymphoblastic leukemia (T-ALL): Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH). Current research in translational medicine 2023. link